CL2015001971A1 - Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. - Google Patents

Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.

Info

Publication number
CL2015001971A1
CL2015001971A1 CL2015001971A CL2015001971A CL2015001971A1 CL 2015001971 A1 CL2015001971 A1 CL 2015001971A1 CL 2015001971 A CL2015001971 A CL 2015001971A CL 2015001971 A CL2015001971 A CL 2015001971A CL 2015001971 A1 CL2015001971 A1 CL 2015001971A1
Authority
CL
Chile
Prior art keywords
heterocycle
treatment
methods
viral diseases
compounds substituted
Prior art date
Application number
CL2015001971A
Other languages
English (en)
Inventor
Deyou Sha
Wensheng Yu
Ling Tong
Josephe A Kozlowski
Oleg Selyutin
Lei Chen
Jae-Hun Kim
Razia Rizvi
Bandarpalle Shankar
Bin Hu
Bin Zhong
Dahai Wang
Jinglai Hao
Wei Wei
Tao Ji
shuai Zan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2015001971A1 publication Critical patent/CL2015001971A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

COMPUESTOS DERIVADOS DE TETRACICLOS 2-(2-PIRAZOL)-1,3-DIAZOL-5-IL DISUSTITUIDOS; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; USO DE ESTA COMPOSICION PARA INHIBIR LA REPLICACION DEL VIRUS DE LA HEPATITIS C (VHC) O PARA TRATAR UNA INFECCION POR VHC; Y METODO PARA TRATAR EL VHC.
CL2015001971A 2013-01-16 2015-07-13 Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. CL2015001971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/000038 WO2014110687A1 (en) 2013-01-16 2013-01-16 Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

Publications (1)

Publication Number Publication Date
CL2015001971A1 true CL2015001971A1 (es) 2015-10-23

Family

ID=51208906

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001971A CL2015001971A1 (es) 2013-01-16 2015-07-13 Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.

Country Status (26)

Country Link
US (1) US9555038B2 (es)
EP (1) EP2945952B1 (es)
JP (3) JP6093451B2 (es)
KR (1) KR101748974B1 (es)
CN (1) CN105073755B (es)
AP (1) AP2015008625A0 (es)
AR (1) AR094496A1 (es)
AU (1) AU2013374112B2 (es)
BR (1) BR112015016325A2 (es)
CA (1) CA2898049C (es)
CL (1) CL2015001971A1 (es)
CR (1) CR20150378A (es)
DO (1) DOP2015000169A (es)
EA (1) EA030554B1 (es)
EC (1) ECSP15035530A (es)
HK (1) HK1211290A1 (es)
IL (1) IL239832A0 (es)
MA (1) MA38315B1 (es)
MD (1) MD20150075A2 (es)
MX (1) MX356203B (es)
PE (1) PE20151892A1 (es)
PH (1) PH12015501560A1 (es)
SG (1) SG11201505536RA (es)
TN (1) TN2015000293A1 (es)
TW (1) TW201441231A (es)
WO (2) WO2014110687A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
US10457690B2 (en) 2015-06-04 2019-10-29 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
US20180228826A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023716A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20190002480A1 (en) * 2015-12-21 2019-01-03 Merck Sharp & Dohme Corp. Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
WO2017181383A1 (en) 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
EP3473639B1 (en) * 2016-06-21 2023-03-29 Zhejiang Palo Alto Pharmaceuticals, Inc Hepatitis c virus inhibitor and application
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
CN109206396B (zh) * 2017-07-05 2023-03-28 上海迪赛诺化学制药有限公司 2-c-甲基-4,5-o-(1-甲基乙烯基)-d-阿拉伯糖酸乙酯的制备方法
CN109232612A (zh) * 2017-07-11 2019-01-18 周龙兴 抑制丙肝病毒的化合物、药物组合物及其用途
US20210361663A1 (en) * 2018-10-26 2021-11-25 Merck Sharp & Dohme Corp. Formulations of Antiviral Compounds
TW202317145A (zh) * 2021-06-17 2023-05-01 美商亞堤製藥公司 有利之抗hcv組合療法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
MXPA03002410A (es) 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
US7407649B2 (en) 2003-07-10 2008-08-05 Paradigm Therapeutics Ltd Silicon compounds and their use
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PL1719773T3 (pl) 2004-02-24 2009-08-31 Japan Tobacco Inc Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
US20110104109A1 (en) 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
AU2006267077A1 (en) 2005-07-14 2007-01-18 Irm Llc Heterotetracyclic compounds as TPO mimetics
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr) 2005-12-16 2007-06-22 Inst Nat Sante Rech Med Nouveaux composes interagissant avec pea-15
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010535766A (ja) 2007-08-09 2010-11-25 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのケイ素誘導体
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0822323A2 (pt) 2008-02-13 2015-06-16 Bristol Myers Squibb Co Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
CA2731177C (en) 2008-07-22 2013-10-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
WO2010041687A1 (ja) 2008-10-09 2010-04-15 コニカミノルタホールディングス株式会社 有機光電変換素子、太陽電池及び光センサアレイ
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
EP2373172B1 (en) 2008-12-03 2013-07-17 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CN102427729B (zh) * 2009-03-27 2014-09-03 默沙东公司 丙型肝炎病毒复制的抑制剂
EP2435421A1 (en) 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
WO2012040923A1 (en) * 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
MX2013003631A (es) * 2010-09-29 2013-10-01 Merck Sharp & Dohme Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
KR20130120469A (ko) * 2010-09-29 2013-11-04 머크 샤프 앤드 돔 코포레이션 폴리시클릭 헤테로사이클 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases

Also Published As

Publication number Publication date
JP6093451B2 (ja) 2017-03-08
JP6417380B2 (ja) 2018-11-07
TW201441231A (zh) 2014-11-01
SG11201505536RA (en) 2015-08-28
ECSP15035530A (es) 2017-08-31
IL239832A0 (en) 2015-08-31
EP2945952B1 (en) 2019-08-28
WO2014110705A1 (en) 2014-07-24
JP6148779B2 (ja) 2017-06-14
EP2945952A1 (en) 2015-11-25
AU2013374112B2 (en) 2016-11-17
CN105073755B (zh) 2017-08-18
KR20150104630A (ko) 2015-09-15
MA38315B1 (fr) 2018-05-31
BR112015016325A2 (pt) 2017-08-22
US9555038B2 (en) 2017-01-31
CN105073755A (zh) 2015-11-18
EA201591328A1 (ru) 2015-11-30
AU2013374112A1 (en) 2015-07-16
US20150335648A1 (en) 2015-11-26
AP2015008625A0 (en) 2015-07-31
MX2015009225A (es) 2015-10-15
MX356203B (es) 2018-05-18
EA030554B1 (ru) 2018-08-31
WO2014110705A9 (en) 2015-03-05
PH12015501560A1 (en) 2015-09-21
EP2945952A4 (en) 2016-07-20
PE20151892A1 (es) 2015-12-24
JP2017075158A (ja) 2017-04-20
DOP2015000169A (es) 2015-12-31
HK1211290A1 (en) 2016-05-20
WO2014110687A1 (en) 2014-07-24
CR20150378A (es) 2015-12-09
MD20150075A2 (ro) 2016-02-29
JP2016510321A (ja) 2016-04-07
TN2015000293A1 (en) 2016-10-03
CA2898049C (en) 2018-04-17
MA38315A1 (fr) 2017-02-28
KR101748974B1 (ko) 2017-06-19
CA2898049A1 (en) 2014-07-24
JP2017095450A (ja) 2017-06-01
AR094496A1 (es) 2015-08-05

Similar Documents

Publication Publication Date Title
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2018002549A1 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001936A1 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001811A1 (es) Compuestos heterociclos derivados de 3-(azepan-1-il-sulfonil)-n-fenilbenzamida; composición farmacéutica, útiles para tratar y prevenir la infección por vhb
GT201300093A (es) Compuestos antivirales
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
UY36904A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
UY36903A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue